NHS Introducing Improved Anti-Smoking Pill to the Public
NHS England announced the introduction of a new anti-smoking pill to aid in smoking cessation efforts. The pill, varenicline, helps reduce nicotine cravings and block their effects on the brain, making it as effective as vapes in aiding people to quit smoking. It is more effective than nicotine-replacement gum or patches for this purpose. Patients will need a prescription from their GP or an NHS stop-smoking service to obtain varenicline.
The previous smoking cessation pill used in the UK, Champix, was withdrawn from the market in 2021 due to the discovery of an impurity. Varenicline, now approved as safe by the MHRA, will be provided by Teva UK as the new generic version for the NHS.
Impact on NHS, Economy
NHS Chief Executive Amanda Pritchard praised the new drug as a “game-changer” for those wanting to quit smoking. She highlighted that it aligns with the government’s 10-year health plan by facilitating a shift towards prevention. The use of varenicline is projected to assist over 85,000 individuals in quitting smoking annually and prevent up to 9,500 smoking-related deaths over the next five years.
NHS England aims to deliver effective treatment options for patients and save over £500 million in taxpayer costs. The drug will complement the existing NHS Stop Smoking Services in England.
